A phase 2 open-label trial evaluated transdermal CBD for 22q11.2 deletion syndrome in children, demonstrating tolerability with preliminary behavioral improvements. While promising for this rare genetic condition, controlled trials are needed to establish definitive therapeutic benefits before clinical implementation.
Phase 2, open-label INSPIRE trial to assess the tolerability and effectiveness of transdermal cannabidiol gel in children and adolescents with 22q11.2 deletion syndrome (ZYN2-CL-031).
CED Clinical Relevance #64Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. 🔬 Evidence Watch | CED Clinic CbdPediatricNeurodevelopmentalTransdermalOpen-Label JournalJournal of neurodevelopmental disordersStudy TypeOpen-Label TrialPopulationHuman participants Why This Matters22q11.2 deletion syndrome affects 1 in...
Cannabinoid Clinical Trials: CBD Gel Safety in Fragile X
Clinical Takeaway Transdermal cannabidiol gel (ZYN002) has been studied in children and adolescents with Fragile X syndrome through an open-label extension trial focused on long-term safety and tolerability. Early interim data suggest...